Lumosa Therapeutics Co., Ltd. has signed an exclusive licensing agreement with GUFIC Biosciences Limited in India for LT1001 long-acting analgesic injection. Lumosa will be responsible for product supply, while GUFIC will be responsible for clinical trials, drug license application, and marketing. LT1001 offers an extended analgesic effect, helping to improve patients' quality of life and reduce the burden on healthcare providers.